Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ohio State University
Headquarters: Columbus, OH, United States of America
Website: http://www.osu.edu
Year Founded: 1870
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Dec 20, 2024
Emerging Company Profile
City: Taking RNAi beyond the liver
Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s
BioCentury | Dec 19, 2024
Product Development
Tertiary lymphoid structures: Key to predicting and improving cancer immunotherapy response?
At least two companies are preparing to take inducers of tertiary lymphoid structure into the clinic
BioCentury | Oct 16, 2024
Discovery & Translation
Science Spotlight: Better genomic predictors for Black AML patients
BioCentury’s roundup of translational innovations also includes a method for continuous base edits, plus updates from Monte Rosa and ImCheck
BioCentury | May 17, 2024
Product Development
Vectorized antibodies are taking gene therapy beyond rare disease
ASGCT presentations showcase cancers, infectious diseases and chronic inflammatory conditions as potential applications of vectorized antibodies
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Feb 9, 2024
Finance
Venture report: Scion’s launch, rounds for Neurona, Attralus and Basking
New firm, affiliated with NYC-based Petrichor, will put $310M fund toward company creation
BioCentury | May 3, 2023
Discovery & Translation
Rapid identification of improved antibody variants; plus peptide-assisted genome editing and more
BioCentury’s roundup of translational news
BioCentury | Feb 3, 2023
Management Tracks
Vessey to leave BMS in July
Plus: Nichols joining enGene as CEO and updates from Invivyd, Exai and more
BioCentury | Oct 31, 2022
Discovery & Translation
Maze identifies two regulators of ALS target ATXN2; plus updates from Black Diamond and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 191